Terns Pharmaceuticals, Inc.TERNNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-2.14%
↓ 134% below average
Average (23q)
6.32%
Historical baseline
Range
High:60.03%
Low:-31.76%
Volatility
1451.5%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -2.14% |
| Q2 2025 | 8.72% |
| Q1 2025 | 3.98% |
| Q4 2024 | 18.69% |
| Q3 2024 | -17.34% |
| Q2 2024 | -1.26% |
| Q1 2024 | 6.46% |
| Q4 2023 | 17.72% |
| Q3 2023 | 4.81% |
| Q2 2023 | -17.03% |
| Q1 2023 | 60.03% |
| Q4 2022 | -12.36% |
| Q3 2022 | 40.39% |
| Q2 2022 | 6.47% |
| Q1 2022 | -14.01% |
| Q4 2021 | 32.28% |
| Q3 2021 | 20.00% |
| Q2 2021 | -31.76% |
| Q1 2021 | 12.42% |
| Q4 2020 | 43.78% |
| Q3 2020 | -29.00% |
| Q2 2020 | 5.07% |
| Q1 2020 | -4.13% |
| Q4 2019 | 0.00% |